SpliSense Israeli Startup Offers Cystic Fibrosis Treatment
SpliSense Israeli Startup Offers Cystic Fibrosis Treatment The company just raised $28.5 million. Gili Hart, PhD, Executive Officer, SpliSense. (company pic) Israeli medtech startup SpilSense develops transformative mRNA-altering therapies for cystic fibrosis (CF) and other genetic pulmonary diseases. The company just raised $28.5 million in a Series B funding round. Orbimed, Israel Biotech Fund, Biotel […]
Continue Reading